

*ATB Therapeutics –
Next immunotherapeutics generation*

Bertrand Magy, CEO ATB Therapeutics


12 MARS
MAART
2019

MARCHE-EN-FAMENNE

*Colloque
Dr Paul Janssen*

ATB Therapeutics – Next immunotherapeutics generation

Versatile platform
Unique manufacturing abilities
Oncology Market



3 keys of success and differentiation

Key 1 - Funding & advises



DGO6



INVESTSUD

votre associé capital & croissance



Fournier-Majoie
Foundation

Financial structure and Strategic development

12 MARS
MAART
2019

MARCHE-EN-FAMENNE

Colloque
Dr Paul Janssen

3 keys of success and differentiation

Key 2 - Facilities and Expertise



- Offices
- BL2 Laboratories fully equipped
- Characterization assays development
- In vitro & in vivo preclinical development
- Quality control expertise



- Modular production container



12 MARS
MAART
2019

MARCHE-EN-FAMENNE

*Colloque
Dr Paul Janssen*

3 keys of success and differentiation

Key 3 - Experts & Advisors

**KOL : business &
technology relevance**

Project Challenging
POC choices relevance
Unmet need targeted

**Advisors: strategic development
and value creation**

IP driven development
Market driven development

12 MARS
MAART
2019

MARCHE-EN-FAMENNE

*Colloque
Dr Paul Janssen*

ATB Therapeutics

Spinventure

 **INVESTSUD**
votre associé capital & croissance



Wallonie

 **Fournier-Majoie**
Foundation

 **IDELUX**

 **CER**
Groupe

ATB Therapeutics is looking for midterm financial partner
bertrand.magy@atbtherapeutics.com 084 84 02 49 – 0478 62 50 59

12 MARS
MAART
2019

MARCHE-EN-FAMENNE

Colloque
Dr Paul Janssen